PMID- 15582898
OWN - NLM
STAT- MEDLINE
DCOM- 20041220
LR  - 20181201
IS  - 0007-4551 (Print)
IS  - 0007-4551 (Linking)
VI  - 91
IP  - 5
DP  - 2004 May 1
TI  - Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid 
      tumors.
PG  - E70-6
AB  - Recent advances in cancer therapy have resulted in the development of drugs that 
      target mechanisms involved in neoplastic change and angiogenesis. One example is 
      gefitinib ('Iressa', ZD1839), an orally-active epidermal growth factor receptor 
      tyrosine kinase inhibitor (EGFR-TKI) that blocks EGFR signaling in vitro, thereby 
      inhibiting the growth, proliferation and survival of many solid tumors. Clinical 
      trial data show that gefitinib monotherapy is generally well tolerated in 
      patients with a wide range of tumor types (including lung, head and neck, colon, 
      breast, and prostate cancers). The most common adverse events (AEs) were mild and 
      reversible skin and gastrointestinal disorders (National Cancer Institute common 
      toxicity criteria grade 1/2). Few drug-related grade 3/4 skin and 
      gastrointestinal disorders were observed, and drug-related hematologic AEs were 
      uncommon. The clinical benefit of gefitinib in non-small-cell lung cancer 
      (NSCLC), head and neck, colon, breast, and prostate cancer is being investigated, 
      as antitumor activity has been observed in a range of solid tumors, including 
      NSCLC. In two large phase II NSCLC trials (IDEAL ['Iressa' Dose Evaluation in 
      Advanced Lung Cancer] 1 and 2) objective tumor responses of 18.4% and 11.8%, and 
      disease control rates (complete and partial responses plus stable disease) of 
      54.4% and 42.2%, respectively, were seen in patients given 250 mg/day gefitinib. 
      Additionally, disease-related symptoms improved in 40.3% and 43.1% of patients, 
      and improved quality of life was experienced by 23.9% and 34.3% patients in IDEAL 
      1 and 2, respectively. Furthermore, the majority of patients who had an objective 
      response also experienced symptom improvement. Gefitinib has been approved for 
      the treatment of advanced NSCLC in Japan, the USA, and other countries. This 
      review discusses the potential of gefitinib in a wide range of solid tumors. 
      'Iressa' is a trademark of the AstraZeneca group of companies.
FAU - Von Pawel, Joachim
AU  - Von Pawel J
AD  - Asklepios Fachkliniken, Robert-Koch-Allee 2, 82131 Gauting, Germany.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20040501
PL  - France
TA  - Bull Cancer
JT  - Bulletin du cancer
JID - 0072416
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Quinazolines)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - S65743JHBS (Gefitinib)
SB  - IM
MH  - Antineoplastic Agents/pharmacokinetics/*therapeutic use
MH  - Breast Neoplasms/drug therapy
MH  - Carcinoma, Non-Small-Cell Lung/drug therapy
MH  - Carcinoma, Squamous Cell/drug therapy
MH  - Clinical Trials, Phase I as Topic
MH  - Colorectal Neoplasms/drug therapy
MH  - ErbB Receptors/*antagonists & inhibitors
MH  - Female
MH  - Gefitinib
MH  - Head and Neck Neoplasms/drug therapy
MH  - Humans
MH  - Lung Neoplasms/drug therapy
MH  - Male
MH  - Neoplasms/*drug therapy/metabolism
MH  - Prostatic Neoplasms/drug therapy
MH  - Quinazolines/pharmacokinetics/*therapeutic use
RF  - 46
EDAT- 2004/12/08 09:00
MHDA- 2004/12/21 09:00
CRDT- 2004/12/08 09:00
PHST- 2004/12/08 09:00 [pubmed]
PHST- 2004/12/21 09:00 [medline]
PHST- 2004/12/08 09:00 [entrez]
PST - epublish
SO  - Bull Cancer. 2004 May 1;91(5):E70-6.